Delivery Order SPE2DR25D1053-SPE2DR26FT211
- Not listed
- The Defense Logistics Agency awarded a $11,624.35 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Lorbrena 100 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $11,624.35 delivery order to AmerisourceBergen Drug Corp for the supply of Lorbrena 100 mg tablets (30-count packages) under a firm fixed-price contract. The delivery order is scheduled for completion by September 18, 2025, and will be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation, reflecting the vendor's capability to meet federal pharmaceutical procurement...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of Lorbrena 100 mg tablets (30-count units) with a ceiling value of $23,248.72. This firm fixed-price delivery order is scheduled for completion by July 16, 2025, and will be fulfilled from the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive, competitively awarded transaction, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lorbrena 100mg tablets (30-count packaging) under a firm fixed-price contract valued at $24,500.56. The delivery order, issued on October 20, 2025, carries an ultimate completion date of November 10, 2025, and represents a non-competitive award. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,624.35 to AmerisourceBergen Drug Corp for the supply of Lorbrena 100 mg tablets (30-count units) with an ultimate completion date of August 19, 2025. This is a firm fixed price contract with no set-aside designation, awarded competitively on July 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Lorbrena 25 mg tablets (30-count) on September 22, 2025, with a ceiling value of $11,624.34 and an ultimate completion date of October 14, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $11,624.35 to AmerisourceBergen Drug Corp for 30-count tablets of Lorbrena 100 mg, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Lorbrena 100mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $23,248.70, is scheduled for completion by August 11, 2025, with performance to be executed at the contractor's Conshohocken, Pennsylvania location. The award was made on a competitive basis with no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Lorbrena 100 mg tablets in quantities of 30. This firm fixed-price delivery order, valued at $11,624.35, represents a competitive award with no set-aside designation and is scheduled for completion by September 16, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $11,624.35 to AmerisourceBergen Drug Corp for the supply of Lorbrena 100 mg tablets (30-count units) under a firm fixed price contract. The award, issued on June 2, 2025, with an ultimate completion date of June 24, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location in the same...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT211Delivery Order
The Defense Logistics Agency awarded a $24.5K delivery order to AmerisourceBergen Drug Corp for 30 tablets of Lorbrena 100 mg on October 22, 2025, with completion scheduled for November 13, 2025. This firm fixed-price contract, issued without set-aside provisions, will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply transaction supporting federal medical procurement needs through competitive award procedures. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9M through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The IDC enables the company to supply an extensive range of pharmaceutical products and medical commodities to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a significant federal contract portfolio with DLA and demonstrates capability to fulfill federal medical supply requirements across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.5k | 10/22/25 |